全文获取类型
收费全文 | 3746篇 |
免费 | 371篇 |
国内免费 | 46篇 |
学科分类
医药卫生 | 4163篇 |
出版年
2024年 | 13篇 |
2023年 | 126篇 |
2022年 | 132篇 |
2021年 | 176篇 |
2020年 | 171篇 |
2019年 | 206篇 |
2018年 | 219篇 |
2017年 | 173篇 |
2016年 | 174篇 |
2015年 | 158篇 |
2014年 | 201篇 |
2013年 | 359篇 |
2012年 | 161篇 |
2011年 | 170篇 |
2010年 | 136篇 |
2009年 | 168篇 |
2008年 | 138篇 |
2007年 | 138篇 |
2006年 | 136篇 |
2005年 | 117篇 |
2004年 | 99篇 |
2003年 | 95篇 |
2002年 | 78篇 |
2001年 | 69篇 |
2000年 | 49篇 |
1999年 | 41篇 |
1998年 | 41篇 |
1997年 | 43篇 |
1996年 | 29篇 |
1995年 | 31篇 |
1994年 | 29篇 |
1993年 | 20篇 |
1992年 | 29篇 |
1991年 | 19篇 |
1990年 | 21篇 |
1989年 | 16篇 |
1988年 | 22篇 |
1987年 | 23篇 |
1986年 | 21篇 |
1985年 | 15篇 |
1984年 | 23篇 |
1983年 | 15篇 |
1982年 | 5篇 |
1981年 | 18篇 |
1980年 | 7篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1973年 | 2篇 |
排序方式: 共有4163条查询结果,搜索用时 15 毫秒
101.
K. Fischer † J. Astermark ‡ J. G. Van Der Bom †§ R. Ljung ¶ E. Berntorp ‡ D. E. Grobbee§ H. M. Van Den Berg† 《Haemophilia》2002,8(6):753-760
A multicentre study was performed in Sweden and the Netherlands, comparing effects of two prophylactic regimens in 128 patients with severe haemophilia, born 1970-90. 42 Swedish patients (high-dose prophylaxis), were compared with 86 Dutch patients (intermediate-dose prophylaxis). Patients were evaluated at the date of their last radiological score according to Pettersson. Annual clotting factor consumption and bleeding frequency were registered for a period of three years before evaluation. Patients in the high-dose group were younger at evaluation (median 15.2 vs. 17.9 years), started prophylaxis earlier (median 2 vs. 5 years), and used 2.19 times more clotting factor kg-1 year-1. Patients treated with high-dose prophylaxis had fewer joint bleeds (median 0.3 year-1 vs. 3.3 year-1) and the proportion of patients without arthropathy as measured by the Pettersson score was higher (69% vs. 32%), however, the age-adjusted difference in scores (median 0 points vs. 4 points) was small and at present not statistically significant. Clinical scores and quality of life were similar. These findings suggest that, compared with intermediate-dose prophylaxis, high-dose prophylaxis significantly increases treatment costs and reduces joint bleeds over a period of 3 years, but only slightly reduces arthropathy after 17 years of follow-up. 相似文献
102.
The overall effectiveness of prophylaxis in severe haemophilia 总被引:1,自引:1,他引:1
The aim of this retrospective review was to assess the overall effectiveness of prophylaxis when compared with on-demand treatment of haemophilic patients. Twenty-five children (22 with severe haemophilia A and three with severe haemophilia B) were evaluated. Five haemophilia A patients received primary prophylaxis (instituted before the onset of any joint bleed) while the other 17 haemophilia A and all three haemophilia B patients were on secondary prophylaxis. We compared factor usage, number of bleeding episodes, emergency room (ER) visits and hospitalizations while on prophylaxis to those while on demand therapy. All subjects were male, the median age at time of review was 11.4 years and at start of prophylaxis was 4.5 years. Thirteen of the 25 patients (52%) required indwelling venous catheters for access, seven of these had one or more (one-six) episodes of line sepsis. Haemophilia A patients received an average of 23.8 U kg(-1) (20-30 U kg(-1)) of recombinant factor VIII three times a week while haemophilia B patients received 50 U kg(-1) recombinant FIX twice weekly. There was a significant reduction in the mean number of major bleeds on prophylaxis from 15.5 to 1.9 per year and a significant decrease in target joints, ER visits and hospitalizations. Although factor usage per year was higher on prophylaxis, there was an overall reduction in number of bleeds and resultant decrease in hospitalizations and ER visits. By preventing new target joints, prophylaxis can lead to reduction in long-term morbidity and a better quality of life despite increased central lines and higher factor usage. 相似文献
103.
ObjectiveWe aimed to compare the efficacy and risks of proton pump inhibitor (PPI) versus histamine-2 receptor blocker (H2B) use for stress ulcer prophylaxis (SUP) in critically ill patients with sepsis and risk factors for gastrointestinal bleeding (GIB).MethodsIn this retrospective cohort study, we used the Medical Information Mart for Intensive Care III Clinical Database to identify critically ill adult patients with sepsis who had at least one risk factor for GIB and received either an H2B or PPI for ≥48 hours. Propensity score matching (PSM) was conducted to balance baseline characteristics. The primary outcome was in-hospital mortality.ResultsAfter 1:1 PSM, 1056 patients were included in the H2B and PPI groups. The PPI group had higher in-hospital mortality (23.8% vs. 17.5%), GIB (8.9% vs. 1.6%), and pneumonia (49.6% vs. 41.6%) rates than the H2B group. After adjusting for risk factors of GIB and pneumonia, PPI use was associated with a 1.28-times increased risk of in-hospital mortality, 5.89-times increased risk of GIB, and 1.32-times increased risk of pneumonia.ConclusionsAmong critically ill adult patients with sepsis at risk for GIB, SUP with PPIs was associated with higher in-hospital mortality and higher risk of GIB and pneumonia than H2Bs. 相似文献
104.
105.
Chantal Bottex Yves P. Gauthier Ralf M. Hagen Ernst J. Finke Wolf D. Splettstösser François M. Thibault 《Immunopharmacology and immunotoxicology》2013,35(4):565-583
Melioidosis is a severe gram-negative infection caused by the facultative intracellular bacterium Burkholderia pseudomallei, which is responsible for a broad spectrum of symptoms in both humans and animals. No licensed vaccine currently exists. This study evaluated the protective effect of a monoclonal antibody (Mab Ps6F6) specific to B. pseudomallei exopolysaccharide in an outbred murine model of sub-acute melioidosis. When administered before the infectious challenge, Ps6F6 significantly increased resistance to infection and restrained bacterial burden in the spleen over a 30-days period. Patterns of IFN-γ production were similar in the treated and non treated groups of mice. However, Ps6F6 lowered IFN-γ levels over the duration of the assay period, except on day 1, suggesting a transient and rapid production of IFN-γ under Ps6F6 control. Minor but persisting increases occurred in IL-12 levels while TNF-α was detected only in the controls at the later stages of infection. No IL-10 secretion was detected in both groups of mice. These data suggest that passive prophylaxis with Mab Ps6F6 provide a moderate and transient induction of inflammatory responses in infected mice but failed to trigger a sterilizing protective immunity. 相似文献
106.
Isao Ohsawa Daisuke Honda Yusuke Suzuki Tomoo Fukuda Keisuke Kohga Eishin Morita Shinichi Moriwaki Osamu Ishikawa Yoshihiro Sasaki Masaki Tago Greg Chittick Melanie Cornpropst Sharon C. Murray Sylvia M. Dobo Eniko Nagy Sharon Van Dyke Lacy Reese Jessica M. Best Heather Iocca Phil Collis William P. Sheridan Michihiro Hide 《Allergy》2021,76(6):1789-1799
107.
《International journal of oral and maxillofacial surgery》2020,49(2):250-263
The purpose of this systematic review was to investigate the efficacy of antibiotic prophylaxis (AP) in intraoral bone grafting procedures for the prevention of postoperative infection (POI). Electronic and manual searches were conducted to identify randomized controlled trials (RCTs). The primary outcome assessed was receptor site POI; secondary outcomes assessed included donor site POI, wound dehiscence, pain, graft failure, need for re-grafting, adverse events, patient satisfaction, and quality of life. A random-effects meta-analysis was conducted to obtain risk ratios of dichotomous data. Four RCTs were selected: one examined AP versus placebo and concluded that there was an increased risk of POI without AP; three examined comparative antibiotic regimens and found no statistically significant difference between them. A meta-analysis of prophylactic regimens, including data from the two RCTs that compared preoperative AP to perioperative AP, indicated no statistically significant difference in POI outcomes (P = 0.94, risk ratio 0.94). It was not possible to conduct further meta-analyses for POIs or for any secondary outcomes due to insufficient published data. The risk of bias assessment indicated an overall unclear risk of bias. On the basis of the present review, there is insufficient evidence to support or refute AP for the prevention of POIs in intraoral bone graft placement procedures. 相似文献
108.
109.
Epidemiology of invasive fungal infections in lung transplant recipients on long‐term azole antifungal prophylaxis 下载免费PDF全文
Pearlie P. Chong Cassie C. Kennedy Matthew A. Hathcock Walter K. Kremers Raymund R. Razonable 《Clinical transplantation》2015,29(4):311-318
Lung transplant recipients (LTR) at our institution receive prolonged and mostly lifelong azole antifungal (AF) prophylaxis. The impact of this prophylactic strategy on the epidemiology and outcome of invasive fungal infections (IFI) is unknown. This was a single‐center, retrospective cohort study. We reviewed the medical records of all adult LTR from January 2002 to December 2011. Overall, 16.5% (15 of 91) of patients who underwent lung transplantation during this time period developed IFI. Nineteen IFI episodes were identified (eight proven, 11 probable), 89% (17 of 19) of which developed during AF prophylaxis. LTR with idiopathic pulmonary fibrosis were more likely to develop IFI (HR: 4.29; 95% CI: 1.15–15.91; p = 0.03). A higher hazard of mortality was observed among those who developed IFI, although this was not statistically significant (hazard ratio [HR]: 1.71; 95% confidence interval [CI] [0.58–4.05]; p = 0.27). Aspergillus fumigatus was the most common cause of IFI (45%), with pulmonary parenchyma being the most common site of infection. None of our patients developed disseminated invasive aspergillosis, cryptococcal or endemic fungal infections. IFI continue to occur in LTR, and the eradication of IFI appears to be challenging even with prolonged prophylaxis. Azole resistance is uncommon despite prolonged AF exposure. 相似文献
110.
Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice 下载免费PDF全文
Mario Fernández‐Ruiz Manuel Arias Josep M. Campistol David Navarro Ernesto Gómez‐Huertas Gonzalo Gómez‐Márquez Juan Manuel Díaz Domingo Hernández Gabriel Bernal‐Blanco Frederic Cofan Luisa Jimeno Antonio Franco‐Esteve Esther González Francesc J. Moreso Carlos Gómez‐Alamillo Alicia Mendiluce Enrique Luna‐Huerta José María Aguado the OPERA Study Group 《Transplant international》2015,28(9):1042-1054
There is notable heterogeneity in the implementation of cytomegalovirus (CMV) prevention practices among CMV‐seropositive (R+) kidney transplant (KT) recipients. In this prospective observational study, we included 387 CMV R+ KT recipients from 25 Spanish centers. Prevention strategies (antiviral prophylaxis or preemptive therapy) were applied according to institutional protocols at each site. The impact on the 12‐month incidence of CMV disease was assessed by Cox regression. Asymptomatic CMV infection, acute rejection, graft function, non‐CMV infection, graft loss, and all‐cause mortality were also analyzed (secondary outcomes). Models were adjusted for a propensity score (PS) analysis for receiving antiviral prophylaxis. Overall, 190 patients (49.1%) received preemptive therapy, 185 (47.8%) antiviral prophylaxis, and 12 (3.1%) no specific intervention. Twelve‐month cumulative incidences of CMV disease and asymptomatic infection were 3.6% and 39.3%, respectively. Patients on prophylaxis had lower incidence of CMV disease [PS‐adjusted HR (aHR): 0.10; 95% confidence interval (CI): 0.01–0.79] and asymptomatic infection (aHR: 0.46; 95% CI: 0.29–0.72) than those managed preemptively, with no significant differences according to the duration of prophylaxis. All cases of CMV disease in the prophylaxis group occurred after prophylaxis discontinuation. There were no differences in any of the secondary outcomes. In conclusion, antiviral prophylaxis was associated with a lower occurrence of CMV disease in CMV R+ KT recipients, although such benefit should be balanced with the risk of late‐onset disease. 相似文献